Global PD-1 and PD-L1 Inhibitors Market Size, Share, Forecast: By Type: PD-1 Inhibitors, PD-L1 Inhibitors; By Application: Hodgkin’s Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, Other Applications; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global PD-1 and PD-L1 Inhibitors Market Overview 
    3.1    Global PD-1 and PD-L1 Inhibitors Market Historical Value (2017-2024) 
    3.2    Global PD-1 and PD-L1 Inhibitors Market Forecast Value (2024-2032)
4    Global PD-1 and PD-L1 Inhibitors Market Landscape
    4.1    Global PD-1 and PD-L1 Inhibitors Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global PD-1 and PD-L1 Inhibitors Product Landscape
        4.2.1    Analysis by Type
        4.2.2    Analysis by Applications
5    Global PD-1 and PD-L1 Inhibitors Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global PD-1 and PD-L1 Inhibitors Market Segmentation 
    6.1    Global PD-1 and PD-L1 Inhibitors Market by Type
        6.1.1    Market Overview
        6.1.2    PD-1 Inhibitors
        6.1.3    PD-L1 Inhibitors 
    6.2    Global PD-1 and PD-L1 Inhibitors Market by Applications
        6.2.1    Market Overview
        6.2.2    Hodgkin’s Lymphoma
        6.2.3    Kidney Cancer
        6.2.4    Melanoma
        6.2.5    Non-Small Cell Lung Cancer
        6.2.6    Other Applications 
    6.3    Global PD-1 and PD-L1 Inhibitors Market by Distribution Channel
        6.3.1    Market Overview
        6.3.2    Hospital Pharmacies
        6.3.3    Retail Pharmacies
        6.3.4    Online Pharmacies 
    6.4    Global PD-1 and PD-L1 Inhibitors Market by Region
        6.4.1    Market Overview
        6.4.2    North America 
        6.4.3    Europe
        6.4.4    Asia Pacific
        6.4.5    Latin America
        6.4.6    Middle East and Africa
7    North America PD-1 and PD-L1 Inhibitors Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe PD-1 and PD-L1 Inhibitors Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific PD-1 and PD-L1 Inhibitors Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America PD-1 and PD-L1 Inhibitors Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa PD-1 and PD-L1 Inhibitors Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Partnership and Collaborations Analysis
    14.1    Analysis by Partnership Instances
    14.2    Analysis by Type of Partnership
    14.3    Analysis by Leading Players
    14.4    Analysis by Geography
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    INDIA CDSCO
        15.1.4    JAPAN PMDA
        15.1.5    Others
16    Supplier Landscape
    16.1    Bristol Myers Squibb
        16.1.1    Financial Analysis
        16.1.2    Product Portfolio
        16.1.3    Demographic Reach and Achievements
        16.1.4    Mergers and Acquisition
        16.1.5    Certifications
    16.2    Merck & Co., Inc.
        16.2.1    Financial Analysis
        16.2.2    Product Portfolio
        16.2.3    Demographic Reach and Achievements
        16.2.4    Mergers and Acquisition
        16.2.5    Certifications
    16.3    Roche
        16.3.1    Financial Analysis
        16.3.2    Product Portfolio
        16.3.3    Demographic Reach and Achievements
        16.3.4    Mergers and Acquisition
        16.3.5    Certifications
    16.4    AstraZeneca
        16.4.1    Financial Analysis
        16.4.2    Product Portfolio
        16.4.3    Demographic Reach and Achievements
        16.4.4    Mergers and Acquisition
        16.4.5    Certifications
    16.5    Pfizer, Inc.
        16.5.1    Financial Analysis
        16.5.2    Product Portfolio
        16.5.3    Demographic Reach and Achievements
        16.5.4    Mergers and Acquisition
        16.5.5    Certifications
    16.6    Eli Lilly and Company
        16.6.1    Financial Analysis
        16.6.2    Product Portfolio
        16.6.3    Demographic Reach and Achievements
        16.6.4    Mergers and Acquisition
        16.6.5    Certifications
    16.7    Sanofi
        16.7.1    Financial Analysis
        16.7.2    Product Portfolio
        16.7.3    Demographic Reach and Achievements
        16.7.4    Mergers and Acquisition
        16.7.5    Certifications
    16.8    Regeneron Pharmaceuticals
        16.8.1    Financial Analysis
        16.8.2    Product Portfolio
        16.8.3    Demographic Reach and Achievements
        16.8.4    Mergers and Acquisition
        16.8.5    Certifications
    16.9    Novartis AG
        16.9.1    Financial Analysis
        16.9.2    Product Portfolio
        16.9.3    Demographic Reach and Achievements
        16.9.4    Mergers and Acquisition
        16.9.5    Certifications
    16.10    BIOCAD
        16.10.1    Financial Analysis
        16.10.2    Product Portfolio
        16.10.3    Demographic Reach and Achievements
        16.10.4    Mergers and Acquisition
        16.10.5    Certifications
    16.11    Cipla Limited
        16.11.1    Financial Analysis
        16.11.2    Product Portfolio
        16.11.3    Demographic Reach and Achievements
        16.11.4    Mergers and Acquisition
        16.11.5    Certifications
    16.12    MacroGenics, Inc.
        16.12.1    Financial Analysis
        16.12.2    Product Portfolio
        16.12.3    Demographic Reach and Achievements
        16.12.4    Mergers and Acquisition
        16.12.5    Certifications
    16.13    Innovent Biologics
        16.13.1    Financial Analysis
        16.13.2    Product Portfolio
        16.13.3    Demographic Reach and Achievements
        16.13.4    Mergers and Acquisition
        16.13.5    Certifications
    16.14    Jiangsu Hengrui Medicine Co., Ltd.
        16.14.1    Financial Analysis
        16.14.2    Product Portfolio
        16.14.3    Demographic Reach and Achievements
        16.14.4    Mergers and Acquisition
        16.14.5    Certifications
    16.15    Mirati Therapeutics
        16.15.1    Financial Analysis
        16.15.2    Product Portfolio
        16.15.3    Demographic Reach and Achievements
        16.15.4    Mergers and Acquisition
        16.15.5    Certifications
17    Model (Additional Insight)
    17.1    Overview 
    17.2    Potential Distributors 
    17.3    Key Parameters for Distribution Partner Assessment 
18    Key Opinion Leaders (KOL) Insights (Additional Insight)
19    Company Competitiveness Analysis (Additional Insight)
    19.1    Very Small Companies
    19.2    Small Companies
    19.3    Mid-Sized Companies
    19.4    Large Companies
    19.5    Very Large Companies
20    Payment Methods (Additional Insight)
    20.1    Government Funded
    20.2    Private Insurance
    20.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.